Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2007, for Healthcare Acquisition Corp. (Note: The input metadata lists "Altimmune, Inc.", but the filing text explicitly identifies the registrant as Healthcare Acquisition Corp., a blank check company formed to acquire a healthcare business). The Company is in the development stage and has signed an agreement and plan of merger with PharmAthene, Inc. dated January 19, 2007. The Company faces a mandatory liquidation by August 3, 2007, if a business combination is not consummated, raising substantial doubt about its ability to continue as a going concern.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 | YTD Inception (2005-2007) |
|---|---|---|---|
| Total Revenues | $486,315 | $405,023 | $2,920,101 |
| Net Income | $340,985 | $204,450 | $1,634,614 |
| EPS (Basic) | $0.03 | $0.02 | N/A |
| Cash and Cash Equivalents | $467,388 | $1,322,615 (End of Q1 2006) | N/A |
| Cash Held in Trust Fund | $71,486,888 | $70,887,371 (End of Q1 2006) | N/A |
| Total Assets | $72,375,242 | $71,738,744 (Dec 31, 2006) | N/A |
| Total Current Liabilities | $1,341,708 | $1,046,195 (Dec 31, 2006) | N/A |
| Stockholders' Equity | $57,454,727 | $57,113,742 (Dec 31, 2006) | N/A |
Note: Revenue consists primarily of interest and dividend income from the Trust Fund. The Company has no operating revenue from commercial activities.
Material Changes vs. Prior Period
- Net Income Increase: Net income for the three months ended March 31, 2007, was $340,985, compared to $204,450 in the same period in 2006. This increase is primarily driven by higher interest and dividend income from the Trust Fund ($479,674 in Q1 2007 vs. $390,713 in Q1 2006).
- Expense Reduction: Total expenses decreased to $124,364 in Q1 2007 from $167,573 in Q1 2006, largely due to a significant reduction in professional fees ($7,625 vs. $45,820).
- Deferred Merger Fees: Deferred merger fees increased significantly to $372,570 from $121,953 at year-end 2006, reflecting costs associated with the proposed merger with PharmAthene, Inc.
- Cash Position: Cash held outside the Trust Fund decreased from $675,305 at December 31, 2006, to $467,388 at March 31, 2007, due to operating expenditures and the increase in deferred merger fees.
Outlook, Risks, and Management Commentary
- Merger Status: The Company has signed an agreement to merge with PharmAthene, Inc. Upon completion, PharmAthene shareholders are expected to own approximately 52% of the combined company. The transaction requires shareholder and regulatory approvals.
- Liquidity and Going Concern: Management believes it has sufficient funds outside the Trust Fund to operate through August 2007. However, the auditor has noted substantial doubt about the Company's ability to continue as a going concern due to the mandatory liquidation date of August 3, 2007, if the merger is not completed.
- Redemption Rights: Public stockholders may redeem their shares for a pro-rata portion of the Trust Fund if they vote against the business combination. Approximately 1,879,060 shares are currently classified as subject to possible redemption.
- Market Risk: The Company is not exposed to significant market risks regarding foreign exchange or commodity prices. Interest rate risk is considered minimal as Trust Fund assets are invested in short-term U.S. Treasury securities or money market funds.
Investor Verification Checklist
- Merger Approval: Verify the status of shareholder votes and regulatory approvals required to consummate the merger with PharmAthene, Inc.
- Liquidation Deadline: Confirm the timeline for closing the transaction against the mandatory liquidation date of August 3, 2007.
- Trust Fund Balance: Monitor the balance of the Trust Fund ($71.5 million) to ensure it remains sufficient to cover potential redemption requests.
- Deferred Fees: Review the utilization of the $372,570 in deferred merger fees and the potential $500,000 success fee payable to the underwriter upon closing.
- Going Concern Status: Assess the likelihood of the merger closing to determine if the "substantial doubt" regarding the going concern assumption will be resolved.